Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
1768
resultados
Última actualización
26/02/2026 [07:17:00]
Resultados 25 a 50 de 1768
Resumen de: JP2025098004A
To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None
Resumen de: CN120877279A
The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).
Resumen de: CN120882881A
The present invention relates generally to methods and diagnostic applications for treating ulcerative colitis. More specifically, the methods and diagnostic applications of the invention relate to the expression profiles of certain gene transcripts in ulcerative colitis patients and the use of the expression profiles of these gene transcripts for therapy and/or diagnosis in subpopulations of patients suffering from ulcerative colitis.
Resumen de: CN120859955A
The invention discloses a xylosidase response type chemiluminescent microsphere, a preparation method thereof and application of the xylosidase response type chemiluminescent microsphere in colitis in-situ diagnosis and treatment. The preparation method comprises the following steps: firstly, synthesizing a novel chemiluminescent probe specifically responsive to xylosidase and hyperbranched polyxylose targeting intestinal flora, then coupling the chemiluminescent probe and the hyperbranched polyxylose to prepare a functional diagnosis and treatment agent, and preparing the xylosidase responsive chemiluminescent microspheres through an electrospray technology. The xylose enzyme response type chemiluminescent microspheres provided by the invention can be delivered by oral administration, release a functional diagnosis and treatment agent in a pH environment of colon, monitor the activity of probiotics in the intestinal tract in vivo in situ, synchronously realize targeted regulation and control of the activity of the probiotics in the colon, and promote up-regulation of tight junction protein in the intestinal tract and tissue repair and regeneration.
Resumen de: US2025332230A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: US2025334593A1
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Resumen de: WO2025226885A1
The present invention relates to a biomarker associated with intestinal inflammation, and more particularly, to methods for diagnosing or identifying a risk of developing intestinal inflammation using mitochondrial DNA and methods of treating disorders associated with intestinal inflammation.
Resumen de: WO2025224462A1
The invention relates to DNA methylation and gene expression signatures for assessing the severity of IBD in a patient, monitoring the progression of IBD in a patient, and/or determining the efficacy of a therapeutic agent for treating IBD in a patient. The DNA methylation and gene expression signatures of the invention can also be used for the differential diagnosis of Crohn's Disease or Ulcerative Colitis in a patient having or suspected of having IBD. The invention further relates to intestinal epithelial organoids (IEOs) for predicting the efficacy of therapeutic agents and for screening agents for use in treating IBD. The invention further relates to therapeutic agents for use in treating IBD.
Resumen de: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Resumen de: JP2025161855A
To provide compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating γδ T cells (e.g., Vγ4+ cells).SOLUTION: Particular embodiments include: Vγ4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using Vγ4+ cells or gene therapy; and methods of identifying a subject having mutations associated with inflammation of a gut. Compositions and methods of the invention can be used in treatment of inflammation and cancer of the gut.SELECTED DRAWING: None
Resumen de: CN120831477A
The invention discloses a novel target of PPP2R1A as an anti-inflammatory therapeutic drug and application of the novel target, it is found for the first time that knock-down of PPP2R1A can significantly inhibit expression of an anti-inflammatory active compound PB in NF-kB, TNF-alpha and IL-1beta inflammatory factors in human colon tumor cells, and at present, the relationship between PPP2R1A protein and inflammation has not been researched. The invention provides a novel drug target for treatment of inflammatory diseases in the field, provides a practical and effective screening method for discovery of inflammation treatment leading drugs, provides a scientific basis for clinical treatment of ulcerative colitis, and has a good application prospect in the aspect of anti-inflammation.
Resumen de: WO2025218552A1
Provided herein are an antibody or antigen binding fragment that specifically recognizes and/or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.
Resumen de: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Resumen de: CN120818056A
The invention discloses an antibody or an antigen binding fragment capable of specifically recognizing and/or binding an anti-interleukin 6 receptor. Belongs to the field of antibody engineering. The antibody or the antigen binding fragment provided by the invention has higher biological activity, FcRn affinity and stronger antibody stability, and has a good clinical application prospect.
Resumen de: CN120820665A
The invention discloses a biomarker for identifying superior mesenteric artery dissection related intestinal dysfunction. The biomarker is lysophospholipid. By means of the biomarker, a patient with intestinal dysfunction caused by SISMAD can be recognized in an early stage, operation intervention (mainly stent implantation) can be conducted in time, and malignant consequences such as intestinal necrosis, large-area intestinal resection, short bowel syndrome and infection death are avoided.
Resumen de: CN120818054A
The invention belongs to the field of immunology, and relates to an anti-CEACAM1 single-domain antibody and application thereof. The single-domain antibody is composed of heavy chains, and the heavy chains comprise a heavy chain CDR1 as shown in SEQ ID NO: 28 or SEQ ID NO: 29, a heavy chain CDR2 as shown in any one of SEQ ID NO: 30 to SEQ ID NO: 32, and a heavy chain CDR3 as shown in any one of SEQ ID NO: 33 to SEQ ID NO: 35. Compared with the prior art, the invention has the beneficial effects that the single-domain antibody specifically aiming at CEACAM1 is screened by using a biological genetic engineering technology, and the affinity of the antibody is better.
Resumen de: CN120818614A
The invention discloses a microbial marker for treating Crohn's disease based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dialister insight, Roseburia intestinae, Parabacteroides verdeae, Bacteroides caccae, Blauria obeum, Bacteroides intestinae, Paraprevotella, and a combination of the Bacteroides cactinae, and further comprises the following components in parts by weight: 1, 1, 2, 3, 4, 5, 6, 7, 7, 8, 8, 8, 9, 10, 12, 13, 13, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17 According to the invention, through metagenome sequencing and a machine learning algorithm, the key microbial marker which is significantly related to the symptom improvement of the Crohn's disease in the coprophilous fungus transplantation treatment process is screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of the Crohn's disease.
Resumen de: CN120818052A
The present invention relates to novel antibodies and antibody fragments that specifically bind to IL-15 and to compositions containing said antibodies or antibody fragments. Furthermore, the present invention relates to nucleic acids encoding said antibodies or antibody fragments thereof and host cells comprising the same, as well as related uses. In addition, the invention relates to therapeutic and diagnostic uses of these antibodies and antibody fragments.
Resumen de: CN120789208A
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ulcerative colitis as well as a preparation method and application thereof. The invention discloses a traditional Chinese medicine composition for treating ulcerative colitis. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-60 parts of codonopsis pilosula, 10-50 parts of roasted rhizoma atractylodis macrocephalae, 10-50 parts of roasted radix aucklandiae, 10-50 parts of parched white peony root, 10-50 parts of rhizoma cimicifugae, 10-50 parts of bran-fried Chinese yam, 10-50 parts of myristica fragrans, 20-40 parts of vinegar smoked plum, 10-30 parts of fried fructus chebulae, 10-30 parts of baked ginger and 5-45 parts of honey-fried licorice root. According to the traditional Chinese medicine composition provided by the invention, the level of a proinflammatory marker is remarkably reduced, the balance of M1/M2 macrophages in colon tissues is regulated, the damage of oxidative stress to the colon mucosal barrier can be effectively reversed, and the expression of a PI3K/AKT/mTOR signal channel and HIF-1alpha is regulated, so that the curative effects of relieving inflammatory response and accelerating repair are achieved.
Resumen de: CN120796172A
The invention relates to the technical field of bioengineering, and discloses a construction method of an inflammatory bowel disease model, which comprises the following steps: constructing an inflammatory intestinal barrier by using intestinal cells derived from an inflammatory bowel disease patient; and S20, adding a stimulation solution containing immune cells and/or immune cell secretions into the inflammatory intestinal barrier, and carrying out co-culture to obtain the inflammatory bowel disease model. An inflammatory intestinal barrier constructed by using intestinal cells derived from an inflammatory bowel disease patient and adding immune components can retain IBD disease-related gene and cell shape feature expression characteristics, so that the model is closer to the pathological condition in the body of the patient; and moreover, the actual in-vivo pathological injury progress is better simulated, the bionic property of the model is improved, the injury of unbalanced immune cells to the intestinal tract in IBD pathology is reproduced, and potential drug targets can be found and verified. The invention further discloses an inflammatory bowel disease model and application thereof.
Resumen de: WO2025214468A1
Provided are a new antibody and antibody fragment that specifically bind to IL-15, and a composition containing the antibody or antibody fragment. Furthermore, provided are a nucleic acid encoding the antibody or antibody fragment thereof, a host cell containing same, and the related use. In addition, provided are the therapeutic and diagnostic uses of the antibodies and antibody fragments.
Resumen de: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Resumen de: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Resumen de: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Nº publicación: KR20250148382A 14/10/2025
Solicitante:
중앙대학교산학협력단
Resumen de: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
BOPI
Sede Electrónica
